Korro Bio Inc (KRRO) financials
Korro Bio revenue and earnings by year
Korro Bio's revenue was $6.39 million in the fiscal year to December 31, 2025, up 181.5% from the year before. Net income was -$117 million, -1834.5% of revenue. Since the fiscal year to December 31, 2019, revenue has shrunk 22.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 5 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Revenue | 6 | 2 | 14 | 37 | 29 |
| Revenue growth | 181.5% | -83.9% | -62.0% | 27.8% | — |
| Operating income | -122 | -92 | -84 | -28 | -21 |
| Operating margin | -1906.4% | -4047.1% | -597.3% | -74.5% | -71.4% |
| Net income | -117 | -84 | -85 | -27 | -19 |
| Net margin | -1834.5% | -3680.4% | -602.0% | -71.7% | -64.8% |
| Diluted EPS | -$12.48 | -$9.37 | -$124.50 | -$41.00 | — |
| Free cash flow | -79 | -78 | -79 | -52 | 33 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open KRRO in Markets.
See also: KRRO returns
No forecast, no recommendation. This page describes Korro Bio Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.